Scancell (LON:SCLP) Shares Up 5.1% - Here's What Happened

Key Points

• Scancell Holdings plc saw a share price increase of 5.1%, reaching a high of GBX 10.50 during trading, with over 9.8 million shares changing hands, a significant rise from its average volume.
• The company has a debt-to-equity ratio of -566.79, indicating no debt, and a market capitalization of £112.27 million, enhancing its attractiveness to investors.
• Insider Martin Diggle purchased nearly 45,000 shares at an average price of GBX 9, reflecting insider confidence in the firm's growth potential.

Scancell Holdings plc (LON:SCLP - ) shares rose 5.1% during mid-day trading on Friday . The stock traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.25 ($0.14). Approximately 9,863,690 shares changed hands during trading, an increase of 953% from the average daily volume of 936,871 shares. The stock had previously closed at GBX 9.75 ($0.13).

Scancell Trading Up 5.8%

The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The business's fifty day simple moving average is GBX 9.90 and its 200 day simple moving average is GBX 9.43. The stock has a market cap of £112.27 million, a price-to-earnings ratio of -16.62 and a beta of 0.35.

Insider Activity

In other Scancell news, insider Martin Diggle purchased 44,944 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was acquired at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,343.41). Insiders own 4.96% of the company's stock.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.